18 May 2013
Keywords: fda, priority, review, topotarget, totect, danish, drugmaker
Article | 17 April 2006
Danish drugmaker TopoTarget says that the US Food and Drug Administration has granted priority review status to its marketing
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 August 2006
25 September 2006
17 May 2013
© 2013 thepharmaletter.com